Marksans Pharma Limited (NSE:MARKSANS)

Marksans Pharma Financials Overview

Financials in millions INR. Fiscal year is April - March.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Revenue Revenue Growth	33,915	29,509	26,228	21,774	18,521	14,908
Revenue Growth	24.20%	12.51%	20.46%	17.56%	24.23%	8.33%
Gross Profit Gross Profit Growth	18,905	16,131	14,247	11,034	9,120	7,613
Operating Income Operating Income Growth	6,783	5,026	4,493	3,843	2,877	2,141
Net Income Net Income Growth	5,598	4,179	3,806	3,137	2,663	1,868
Earnings Per Share EPS Growth	12.35	9.22	8.40	6.92	6.41	4.56
EPS Growth	59.26%	9.79%	21.36%	7.96%	40.44%	-21.68%

Revenue by Geography

Chart

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
United States and North America United States and North America Growth	15,335	12,366	9,181	7,746	6,351
Europe and The United Kingdom Europe and The United Kingdom Growth	10,150	10,298	9,430	7,676	6,091
Australia and New Zealand Australia and New Zealand Growth	3,031	2,528	2,188	2,095	1,798
Rest of World Rest of World Growth	994.34	1,037	974.49	1,004	554.8
Total Total Growth	29,509	26,228	21,774	18,521	14,908

Cash & Debt

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Investments Cash & Investments Growth	11,236	9,909	7,060	7,013	7,158	3,467
Total Debt Total Debt Growth	4,646	3,434	3,219	2,441	1,229	1,108
Net Cash (Debt) Net Cash Growth	6,590	6,475	3,841	4,572	5,929	2,359
Net Cash Growth	96.60%	68.59%	-16.00%	-22.88%	151.30%	36.10%
Net Cash Per Share Net Cash Per Share Growth	14.55	14.29	8.48	10.09	14.27	5.76

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Operating Cash Flow Operating Cash Flow Growth	7,045	4,581	2,067	2,304	2,374	992.57
Capital Expenditures CapEx Growth	-1,034	-1,305	-1,729	-2,088	-536.31	-463.3
Free Cash Flow Free Cash Flow Growth	6,010	3,276	337.45	215.69	1,838	529.27
Free Cash Flow Growth	1637.61%	870.81%	56.45%	-88.26%	247.24%	-59.95%

Margins

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Gross Margin	55.74%	54.66%	54.32%	50.67%	49.24%	51.07%
Operating Margin	20.00%	17.03%	17.13%	17.65%	15.53%	14.36%
Pretax Margin	22.13%	19.00%	19.21%	19.45%	18.23%	16.60%
Profit Margin	16.51%	14.16%	14.51%	14.41%	14.38%	12.53%
FCF Margin	17.72%	11.10%	1.29%	0.99%	9.92%	3.55%

Dividends

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Nov 9, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Dividend Per Share Dividend Per Share Growth	0.900	0.900	0.800	0.600	0.500	0.250
Dividend Per Share Growth	12.50%	12.50%	33.33%	20.00%	100.00%	0%
Dividend Yield	0.29%	0.57%	0.36%	0.40%	0.71%	0.55%

Valuation

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Nov 9, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
PE Ratio	24.91	17.01	26.49	21.94	11.98	9.97
Forward PE	22.82	15.10	21.89	17.73	5.39	5.39
P/FCF Ratio	22.92	21.70	298.76	319.14	17.36	35.20
PS Ratio	4.06	2.41	3.84	3.16	1.72	1.25

Data Source: S&P Global Market Intelligence Last updated: Nov 4, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 9, 2026

Data Sources Report a data error